Silence Therapeutics to buy Intradigm through share-swap deal

12/16/2009 | Reuters

The U.K.'s Silence Therapeutics agreed to issue 79.64 million shares to acquire Intradigm, a California biotech firm, to boost its presence in RNAi treatments. Silence Chairman Iain Ross said he hopes the merger will help the firm secure a major partnership with a drugmaker next year.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Mylan Inc.
Washington, DC
Health Care Exchange Account Manager
Kaiser Permanente
San Diego, CA
Director of Actuarial Services, Government Programs
Springfield, OR
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC